A Phase 2/3 pivotal confirmatory clinical trial for OCU410ST
Latest Information Update: 25 Apr 2025
At a glance
- Drugs OCU 410 (Primary)
- Indications Stargardt disease
- Focus Registrational; Therapeutic Use
- 08 Apr 2025 According to an Ocugen media release, Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will participate in a panel addressing the journey of commercializing Advanced Therapy Medicinal Products (ATMPs) including OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy and OCU410ST for Stargardt disease, at the 2025 Cell & Gene Meeting on the Mediterranean being held April 15-17, 2025 at the Rome Cavalieri in Rome, Italy.
- 05 Mar 2025 According to Ocugen media release, EMA granted OMPD for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19 (RP19), and cone-rod dystrophy 3 (CORD3). The EC provided a positive opinion from the EMA's CAT for OCU410ST ATMP classification.
- 05 Mar 2025 New trial record